The Clinical Values of Circulating Tumor Cells and T Lymphocyte Subsets in Predicting a Prognosis of Lung Cancer.

IF 0.7 4区医学 Q4 MEDICAL LABORATORY TECHNOLOGY

Clinical laboratory Pub Date : 2024-10-01 DOI:10.7754/Clin.Lab.2024.230514

Xi Liu, Xiaosong Yan, Junyu Li, Weimin Mao, Feng Jiang

{"title":"The Clinical Values of Circulating Tumor Cells and T Lymphocyte Subsets in Predicting a Prognosis of Lung Cancer.","authors":"Xi Liu, Xiaosong Yan, Junyu Li, Weimin Mao, Feng Jiang","doi":"10.7754/Clin.Lab.2024.230514","DOIUrl":null,"url":null,"abstract":"Background: Lung cancer is the most lethal cancer in men and women. Recently, it has been reported that circu-lating tumor cells (CTCs) are sensitive and reliable biomarkers for tracing relapse and metastasis of cancer patients. Many studies also showed that immune cellular dysfunctions in lung cancer patients are major reasons for cancer development. In this study, we explored the clinical significance of CTCs and T lymphocyte subtypes in lung cancer patients.Methods: A total of 92 patients with diagnosed lung cancer, including 23 squamous-cell carcinoma and 69 adenocarcinoma, were enrolled in this study. Another 10 patients with non-carcinoma nodules in their lungs were also recruited as a control group. Peripheral blood samples were drawn from the patients with lung cancer and from the control cases before the treatment. The identification of CTCs was carried out by a PatrolCTC detection method. The T lymphocyte subtypes were characterized by flow cytometry (FACS). Cytokines interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-17A (IL-17A), interleukin-10 (IL-10), and interferon  (IFN-) were detected by meso scale discovery (MSD) assay.Results: Out of the enrolled patients, 69 (75%) patients with non-small cell lung cancer (NSCLC) were male and 23 (25 %) were female. Smoking and non-smoking history was 50% (46 cases) each. The case numbers for I - IV tumor-node-metastasis (TNM) stages were 23 (25.0%), 28 (30.4%), 16 (17.4%), and 25 (27.2%), respectively. The positive rates of the CTCs before treatment were 8.7% (2/23), 17.6% (5/28), 81.3% (13/16), and 100% (25/25) in stage I, II, III, and IV patients, respectively. Total CTCs, mixed CTCs, and mesenchymal CTCs (MCTCs) were strongly related to the progression-free survival (PFS) of the patients. In addition, total CTCs (≥ 6) and positive MCTCs also significantly correlated with recurrence and metastasis. The patients with high CTCs also had low levels of CD4, CD4/CD8 ratio, IL-2, and IFN. In contrast, IL-10 in high CTCs patients was significant elevated. These results indicate that the CTC numbers in lung cancer patients are an independent indicator for a worse PFS.Conclusions: Higher total CTCs, mixed CTCs, and MCTCs in peripheral blood were significant biomarkers for predicting the prognosis of lung cancer patients. High CTCs also had a strong correlation with weak cellular immunity functions.","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"70 10","pages":""},"PeriodicalIF":0.7000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical laboratory","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7754/Clin.Lab.2024.230514","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Lung cancer is the most lethal cancer in men and women. Recently, it has been reported that circu-lating tumor cells (CTCs) are sensitive and reliable biomarkers for tracing relapse and metastasis of cancer patients. Many studies also showed that immune cellular dysfunctions in lung cancer patients are major reasons for cancer development. In this study, we explored the clinical significance of CTCs and T lymphocyte subtypes in lung cancer patients.

Methods: A total of 92 patients with diagnosed lung cancer, including 23 squamous-cell carcinoma and 69 adenocarcinoma, were enrolled in this study. Another 10 patients with non-carcinoma nodules in their lungs were also recruited as a control group. Peripheral blood samples were drawn from the patients with lung cancer and from the control cases before the treatment. The identification of CTCs was carried out by a PatrolCTC detection method. The T lymphocyte subtypes were characterized by flow cytometry (FACS). Cytokines interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-17A (IL-17A), interleukin-10 (IL-10), and interferon  (IFN-) were detected by meso scale discovery (MSD) assay.

Results: Out of the enrolled patients, 69 (75%) patients with non-small cell lung cancer (NSCLC) were male and 23 (25 %) were female. Smoking and non-smoking history was 50% (46 cases) each. The case numbers for I - IV tumor-node-metastasis (TNM) stages were 23 (25.0%), 28 (30.4%), 16 (17.4%), and 25 (27.2%), respectively. The positive rates of the CTCs before treatment were 8.7% (2/23), 17.6% (5/28), 81.3% (13/16), and 100% (25/25) in stage I, II, III, and IV patients, respectively. Total CTCs, mixed CTCs, and mesenchymal CTCs (MCTCs) were strongly related to the progression-free survival (PFS) of the patients. In addition, total CTCs (≥ 6) and positive MCTCs also significantly correlated with recurrence and metastasis. The patients with high CTCs also had low levels of CD4, CD4/CD8 ratio, IL-2, and IFN. In contrast, IL-10 in high CTCs patients was significant elevated. These results indicate that the CTC numbers in lung cancer patients are an independent indicator for a worse PFS.

Conclusions: Higher total CTCs, mixed CTCs, and MCTCs in peripheral blood were significant biomarkers for predicting the prognosis of lung cancer patients. High CTCs also had a strong correlation with weak cellular immunity functions.

查看原文本刊更多论文

循环肿瘤细胞和 T 淋巴细胞亚群在预测肺癌预后中的临床价值

背景：肺癌是男性和女性中最致命的癌症：肺癌是男性和女性中致死率最高的癌症。最近有报道称，循环肿瘤细胞（CTCs）是追踪癌症患者复发和转移的敏感而可靠的生物标志物。许多研究还表明，肺癌患者的免疫细胞功能障碍是癌症发展的主要原因。本研究探讨了肺癌患者 CTCs 和 T 淋巴细胞亚型的临床意义：方法：本研究共纳入 92 例确诊肺癌患者，包括 23 例鳞状细胞癌和 69 例腺癌患者。另外还招募了 10 名肺部有非癌结节的患者作为对照组。肺癌患者和对照组病例在治疗前均抽取了外周血样本。采用 PatrolCTC 检测方法对 CTC 进行鉴定。T淋巴细胞亚型通过流式细胞术（FACS）进行鉴定。细胞因子白细胞介素-2（IL-2）、白细胞介素-4（IL-4）、白细胞介素-17A（IL-17A）、白细胞介素-10（IL-10）和干扰素（IFN-）：在登记的非小细胞肺癌（NSCLC）患者中，69 名（75%）为男性，23 名（25%）为女性。吸烟史和非吸烟史各占 50%（46 例）。肿瘤-结节-转移（TNM）分期为 I - IV 期的病例数分别为 23 例（25.0%）、28 例（30.4%）、16 例（17.4%）和 25 例（27.2%）。Ⅰ、Ⅱ、Ⅲ和Ⅳ期患者治疗前的 CTC 阳性率分别为 8.7%（2/23）、17.6%（5/28）、81.3%（13/16）和 100%（25/25）。总 CTCs、混合 CTCs 和间质 CTCs（MCTCs）与患者的无进展生存期（PFS）密切相关。此外，总 CTCs（≥ 6）和阳性 MCTCs 与复发和转移也有显著相关性。高CTCs患者的CD4、CD4/CD8比值、IL-2和IFN。相比之下，高CTCs患者的IL-10水平明显升高。这些结果表明，肺癌患者的CTC数量是PFS恶化的独立指标：结论：外周血中较高的总 CTCs、混合 CTCs 和 MCTCs 是预测肺癌患者预后的重要生物标志物。结论：外周血中较高的总CTCs、混合CTCs和MCTCs是预测肺癌患者预后的重要生物标志物，高CTCs还与细胞免疫功能较弱密切相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical laboratory 医学-医学实验技术

CiteScore

1.50

自引率

0.00%

发文量

494

审稿时长

3 months

期刊介绍： Clinical Laboratory is an international fully peer-reviewed journal covering all aspects of laboratory medicine and transfusion medicine. In addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies. The journal publishes original articles, review articles, posters, short reports, case studies and letters to the editor dealing with 1) the scientific background, implementation and diagnostic significance of laboratory methods employed in hospitals, blood banks and physicians'' offices and with 2) scientific, administrative and clinical aspects of transfusion medicine and 3) in addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies.